Scientists uncover natural inflammation 'off switch' with therapeutic potential
Discovery of fat-derived molecules could lead to safer treatments for chronic inflammatory diseases.
1The inflammation paradox
While acute inflammation protects against infection, prolonged activation damages healthy tissues and drives conditions like arthritis and diabetes. The UCL team identified epoxy-oxylipins – fat-derived molecules that naturally terminate inflammatory responses. These compounds act as biological brakes, preventing excessive monocyte accumulation linked to chronic inflammation. The discovery addresses a critical gap in understanding how the body transitions from defense to repair.
2Human-based experimental design
Researchers injected UV-killed E. coli into volunteers' forearms to trigger controlled inflammation without infection. This novel approach allowed direct observation of human immune responses. Participants received GSK2256294, an experimental drug that preserves epoxy-oxylipins by inhibiting the sEH enzyme. The treatment accelerated pain resolution and reduced intermediate monocytes by 60-75% in blood and tissue samples, though visible inflammation markers remained unchanged, suggesting deeper immunological effects.
3Molecular mechanism revealed
The study pinpointed 12,13-EpOME as the key epoxy-oxylipin suppressing p38 MAPK signaling – a pathway driving monocyte transformation into pro-inflammatory forms. Laboratory and human trials using p38 blockers confirmed this mechanism. First author Dr. Bracken notes this represents the first mapping of epoxy-oxylipin activity during human inflammation, with particular relevance to autoimmune conditions where existing treatments broadly suppress immunity rather than restoring balance.
4Clinical implications
The findings suggest sEH inhibitors could be repurposed for rheumatoid arthritis and cardiovascular disease within 3-5 years. Unlike current immunosuppressants, these drugs would enhance the body's natural resolution pathways. Dr. Bracken proposes combining sEH inhibitors with existing arthritis medications to potentially prevent joint damage. Arthritis UK emphasizes the need for such targeted therapies, as chronic pain affects 10 million Britons' mobility, sleep, and quality of life.
5Advantages over current treatments
Existing anti-inflammatories like steroids and biologics carry infection risks by broadly suppressing immunity. The epoxy-oxylipin approach specifically modulates monocyte behavior without compromising overall defense. Professor Gilroy highlights this as the first human study using a clinically approved compound (originally developed for pulmonary hypertension), enabling faster therapeutic translation. The research team has filed patents covering this novel application.
6From animal models to human biology
While earlier mouse studies suggested epoxy-oxylipins' anti-inflammatory effects, their human role remained unclear until this trial. These molecules belong to an understudied signaling system distinct from well-known inflammatory mediators like cytokines. The human data confirms they help transition from active inflammation to recovery – a process previously thought to be passive rather than actively regulated.
7Broader therapeutic potential
Beyond arthritis, sEH inhibitors may benefit 50+ million Americans with chronic inflammatory conditions including atherosclerosis, inflammatory bowel disease, and Alzheimer's. The UCL team estimates this mechanism could yield therapies with 30-50% fewer side effects than current options. Pharmaceutical companies are already exploring partnerships, with Phase II trials for rheumatoid arthritis expected by 2025.
8A paradigm shift in immunology
This discovery challenges the traditional focus on blocking inflammation initiation, instead highlighting resolution as an active therapeutic target. By augmenting natural shutdown pathways rather than suppressing immunity, future treatments could maintain protection while preventing chronic damage. The research opens new avenues for understanding autoimmune diseases and age-related inflammation, potentially impacting global healthcare strategies.